

March 7, 2005

CURRICULUM VITAE

Name: Yehuda Z. Patt, M.D., F.A.C.P.

Professional Address: 1 University of New Mexico
Cancer Research & Treatment Center
900 Camino de Salud N.E., MSC 08-4630
Albuquerque, NM 87131-0001

Home Address: Landmark Apartments
6303 Indian School Road, Apt #1006
Albuquerque, NM 87110

Email: yzpatt@salud.unm.edu

Medical Licensures:

State of Israel
State of Texas: E6563
State of New Mexico: 94-117
State of Maryland: D0059558

Certifications:

1982 American Board of Internal Medicine
1987 American Board of Internal Medicine - Subspecialty of Oncology

Educational History:

9/1959-10/1965 M.D., Hebrew University and Hadassah Medical School
Jerusalem, Israel

1/1966-1/1967 Rotating Internship
Jaffa Government Hospital
Jaffa, Israel

1/1970-12/1974 Residency in Internal Medicine
Sheba Medical Center
Tel-Hashomer Government Hospital
Israel

1/1971-12/1974 Post-Graduate Medical School
Tel-Aviv University
Tel-Aviv Israel

9/1974-6/1975 Training in Immunological Methods
Weitzman Institute of Research
Rehovot, Israel

- 9/1974-6/1975 Chief Resident
Department of Internal Medicine
Tel-Hashomer Hospital
Ramat-Gan, Israel
- 7/1975-6/1976 Medical Oncology Fellowship
Department of Developmental Therapeutics
University of Texas M.D. Anderson Hospital and Tumor Institute,
Houston, Texas

Employment History:

- 7/1/1976-8/31/1977 Faculty Associate
Department of Developmental Therapeutics
M.D. Anderson Hospital and Tumor Institute
Houston, Texas
- 9/1/1977-8/31/1980 Assistant Professor
Assistant Internist
Department of Developmental Therapeutics
M.D. Anderson Hospital and Tumor Institute
Houston, Texas
- 9/1/1980-8/31/1981 Associate Professor
Associate Internist
Department of Developmental Therapeutics
M.D. Anderson Hospital and Tumor Institute
Houston, Texas
- 9/1/1981-8/31/1984 Associate Professor
Associate Internist
Chief, Regional Therapy Service
Department of Clinical Immunology and Biological Therapy
M.D. Anderson Hospital and Tumor Institute
Houston, Texas
- 9/1/1984-8/31/1990 Associate Professor
Associate Internist
Department of Medical Oncology
Section of GI Oncology and Digestive Diseases
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
- 9/1/1984-8/31/2002 Chief, Regional Therapy Service
Department of Gastrointestinal Medical Oncology
Division of Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

| | |
|--------------------|--|
| 9/1/1990-8/31/1999 | Associate Professor Internist Department of GI Oncology and Digestive Diseases The University of Texas M. D. Anderson Cancer Center Houston, Texas |
| 9/1/1999-8/31/2002 | Professor Department of Gastrointestinal Medical Oncology The University of Texas M. D. Anderson Cancer Center Houston, Texas |
| 12/2002-9/30/2004 | Professor of Medicine Department of Medicine Hematology/Oncology Division University of Maryland School of Medicine Baltimore, MD |
| 11/15/2004 | Professor Department of Internal Medicine Division of Hematology/Oncology University of New Mexico School of Medicine Albuquerque, NM |

Professional Memberships:

American Association for Cancer Research
American College of Physicians
American Federation of Clinical Research
American Medical Association
American Society for Clinical Oncology
Harris County Medical Society
Inter-American Society for Chemotherapy
International Society of Immuno-pharmacology
Royal Society of Medicine (London)
Texas Medical Association
The University of Texas M. D. Anderson Associates

Military Service:

2/1967-12/1969 Israel Defense Forces, last rank Captain

Administrative Service:

Institutional Service (The University of Texas M.D. Anderson Cancer Center)

| | |
|----------------|--|
| 1982-1983 | Nursing Liaison Committee |
| 1982-1983 | Medical Practice and Professional Liability Review Committee |
| 1983-1984 | Nursing Liaison Committee |
| 1984-1985 | Disaster Committee |
| 1984-1985 | Institutional Product Standards Committee |
| 1990-1991 | Disaster Committee |
| 1992-1993 | Member, Utilization Subcommittee |
| 1992-present | Member, Medical Practice Subcommittee |
| 1994-present | Coordinator, Liver Tumor Study Group |
| 1995-1997 | Member, Institutional Research Support Committee |
| 1999-2002 | Member, Credentials Committee of the Medical Staff |
| | (The University of Maryland Medical School) |
| 2003-9.30.2004 | IRB ; (Institutional Review Board) |
| 2003-9.30.2005 | Greenebaum Cancer Center CRC (clinical Research Committee) |

National Service

| | |
|------|--|
| 1992 | American Cancer Society Member, Program Planning Committee Workshop on the Pretreatment Diagnostic Management of Colorectal Cancer and Follow-up Management of Recurrent Disease |
| 1997 | Expert Presentation to Arbitration and Panel Immunomedics vs. Pharmacia and Upjohn: The Role of MoAb anti-CEA in the Management of Colorectal Cancer |
| 2000 | Prevention of Liver Cancer Association, Coordinator |

Editor

| | |
|-----------|--|
| 1971-1974 | <i>Regional Cancer Treatment</i> |
| 1992-1997 | <i>New Perspectives in Cancer Diagnosis and Management</i> (Editorial Board/Guest Editor) |

Editorial Reviewer

| | |
|--------------|-------------------------------------|
| 1984-present | <i>Cancer</i> |
| 1988-present | <i>Journal of Clinical Oncology</i> |
| 1989-present | <i>Cancer Research</i> |
| 1997-present | <i>Hepatology</i> |
| 1999-present | <i>Clinical Cancer Research</i> |

International Service

| | |
|------|---|
| 1985 | II International Conference on Advances in Regional Cancer Program Director, Giessen, West Germany |
|------|---|

- 1989 IV International Conference on Advances in Regional Cancer
Program Director, Berchtesgaden, West Germany
- 1991 V International Conference on Advances in Regional Cancer
Program Director, Rosenheim, Germany
- 1995 Schering Plough International Research Group (IRS)
Chairman, Hepatocellular Cancer Study Group
- 1997 Scientific Advisor, The First Annual International Conference on Diagnosis and
Treatment of Hepatic Neoplasm, NYU, Post Graduate Medical School,
New York Medical Center

Teaching Service:

Formal Teaching: Training Programs

| | |
|--|-----------|
| Medical Oncology | 1977-2002 |
| Internal Medicine, Oncology Electives UTHSC Houston, Medical School | 1996-2002 |

Supervisory Teaching

The University of Texas School of Public Health
Ph.D. Dissertation Advisory Committee Member (Manal Hassan, M.D.) 1993

Clinical Fellows

| | |
|---|--------------|
| Dionisio B. Calvo, III, CIBT | 1979 - 1981 |
| Arnold Cyjon, Tel Aviv University Observer | 1981 |
| Numerous Medical Oncology Fellow rotating through the Department of GI Oncology and Digestive Diseases | 1990-present |
| Daniel B. Frost, Surgery | 1984 |
| Ray Peters, CIBT | 1984 |
| Dennie V. Jones, Jr., Medicine | 1990 - 1991 |
| Eugene Tilchen, CIBT | 1980 - 1981 |
| Michael Kusnir M.D. (U. Maryland GCC) | 2002 - 2003 |

Medical and Undergraduate Students

| | |
|---|----------------|
| Omar Fahdli, 2nd year medical student | 1991 |
| Various medical students rotating through teaching service 1-2 months per year | 1977 - present |

Total contact hours over last 5 years: 2500+ hours

Overseas Observers of the working of the Liver Tumor Studies Group

| | |
|-------------------------------|------|
| Dr. Tiravud, Bangkok Thailand | 1995 |
| Dr. Chayut, Concan Thailand | 1995 |

| | | |
|--|------|------|
| Dr. Colleone, Castel Franco, Italy | 1995 | |
| Dr. Kadry Ismail, Menofia/Cairo, Egypt | 1995 | |
| Dr. Ahmed Raouf, Menofia/Cairo, Egypt | 1995 | |
| Ms. Pannipa Chulasugandha, Ph.R/Bangkok, Thailand | 1996 | |
| Dr. Suphon Manoromana/Bangkok, Thailand | | 1996 |
| Dr. Matthias Lorenz/Frankfurt am Main/Germany | 1996 | |
| Dr. Michael Buchel, University of Pretoria, South Africa | 1997 | |
| Dr. Salvatore Tumolo, Azienda Ospedaliera "S. Maria Degli Angeli" Aviano Cancer Center, Italy | | 1997 |
| Dr. Salvatore Tumolo, Azienda Ospedaliera "S. Maria Degli Angeli" Aviano Cancer Center, Italy | | 1988 |
| Prof. Giancarlo Pansini, Univ. of Ferrara, Italy | 1998 | |
| Dr. Isac I. Schnirer, Tel-Aviv University, Israel | 1998 | |

Research Interests:

- I. Viral and Molecular Correlates of Hepatocellular Cancer (HCC)
 - A. The role of Hepatitis C viral (HCV) infection in North American HCC.
 - B. Factors interacting with HCV in the etiology of HCC.
 - C. HCV, alcohol, oxidative stress and HCC.

- II. Prevention of HCC
 - A. Prevention of emerging HCC in cirrhotic patients: a randomized multi-institutional national trial among orthotopic liver transplant (OLT) candidates.

- III. Diagnosis and Therapy of Hepatobiliary Cancers
 - A. Novel systemic therapies in HCC:
 1. Test newer agents that can be tolerated by cirrhotic HCC patients who are unlikely to tolerate conventional chemotherapy.
 2. Antiangiogenic agents.
 3. Hepatic arterial chemotherapy.
 4. Pre-surgical (neoadjuvant) systemic bio-chemotherapy in association with tumor resection or liver transplantation (capecitabine and pegylated interferon).

- IV. Novel regional and systemic treatment of colon:
 - A. Phase II trials of systemic fluoropyrimidines (capecitabine) alternating with CPT-11 for metastatic colorectal cancer refractory (MCRL).
 - B. Neo-adjuvant treatment in resectable CRC in the liver, using capecitabine and oxaliplatin.
 - C. Neo-adjuvant treatment in potentially resectable colorectal cancer with capecitabine and oxaliplatin.
 - D. Integration of new targeted therapies (Bevacizumab, cetuximab) into the treatment of metastatic colo-rectal cancer (mCRC)

Scholarly Achievements

Original Research or Scholarly Articles in Refereed Journals:

1. Patt YZ, Ravid M. A bite of a snake aspis cerastes. Case Report. *Journal of the Israel Medical Association*, 81:85-88, 1971.
2. Patt YZ, Halkin H, Jaffe R. Primary cardiac angio-sarcoma. *Israel Journal of Medical Sciences*, 10:525-528, 1974.
3. Shneyour A, Patt YZ, Trainin N. Trypsin induced increase in intracellular cyclic AMP of lymphocytes. *The Journal of Immunology*, 117:2143-2149, 1976.
4. Patt YZ, Hersh EM, Dicke KA, Spitzer G, Mavligit GM. Suppressor cell activity in cancer patients: A possible role for thymic hormones. *Cancer Treatment Reports*, 62:1763-1768, 1978.
5. Patt YZ, Wallace S, Hersh EM, Hall SW, Menachem YB, Granmayek M, McBride CM, Benjamin RS, Mavligit GM. Hepatic arterial infusion of corynebacterium parvum and chemotherapy. *Surgery Gynecology and Obstetrics*, 147:897-902, 1978.
6. Peters LJ, Mason K, McBride CH, Patt YZ. Enhancement of lung colony-forming efficiency by local thoracic irradiation-interpretation of labeled cell studies. *Radiology*, 126:499-505, 1978.
7. Patt YZ, Hersh EM, Schafer L, Smith TL, Burgess MA, Gutterman JU, Goldstein AL, Mavligit GM. The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma. *Cancer Immunology and Immunotherapy*, 7:131-156, 1979.
8. Mavligit GM, Ishii Y, Patt YZ, Wong W. Local xenogenic graft-versus-host reaction: A practical assessment of T-cell function among cancer patients. *Journal of Immunology*, 123:2185-2188, 1979.
9. Pritchard JD, Mavligit GM, Benjamin RS, Patt YZ, Calvo DB, Hall SW, Bodey GP, Wallace S. Regression of regionally confined melanoma with intraarterial cis-dichlorodiammine platinum (II). *Cancer Treatment Reports*, 63:555-558, 1979.
10. Hersh EM, Patt YZ, Murphy SG, Dicke K, Zander A, Adegbite M, Goldman R. Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients. *Cancer Research*, 40:3141-3146, 1980.
11. Patt YZ, Mavligit GM, Chuang VP, Wallace S, Johnston S, Benjamin RS, Valdivieso M, Hersh EM. Percutaneous hepatic arterial infusion (HAI) of mitomycin C and Floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver. *Cancer*, 46:261-265, 1980.

12. Patt YZ, Mavligit GM, Chuang VP, Faltely J. Arteriovenous carcinoembryonic antigen gradient: Determination by selective angiography for localization of metastatic colorectal cancer. *Archives of Surgery*, 115:1112-1124, 1980.
13. Calvo DB, III, Patt YZ, Wallace S, Chuang VP, Benjamin RS, Pritchard JD, Hersh EM, Bodey GP, Sr., Mavligit GM. Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. *Cancer*, 45:1278-1283, 1980.
14. Dreizen S, McCredie KB, Bodey GP, Keating MJ, Patt YZ. Superficial head and neck metastases in adults with widespread cancer. *Post-Graduate-Medicine*, 67:171-185, 1980.
15. Folkers K, Dahmen J, Ohta M, Stepien H, Leban J, Sakura N, Rampold G, Lundanes E, Rampold G, Goldman R, Patt YZ. Isolation of glutathione from bovine thymus tissue and its significance to research relevant to immune systems. *Biochemical Biophysical Research Communications*, 97: 590-594, 1980.
16. Patt YZ, Chuang VP, Wallace S, Hersh EM, Freireich EJ, Mavligit GM. The palliative role of hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. *Lancet*, 1:349-351, 1981.
17. Chuang VP, Wallace S, Stroehlein J, Yap HY, Patt YZ. Hepatic artery infusion chemotherapy: Gastroduodenal complications. *American Journal of Radiology*, 137:347-350, 1981.
18. Mavligit GM, Benjamin RS, Patt YZ, Jaffe N, Chuang V, Wallace S, Murray J, Ayala A, Johnston S, Hersh EM, Calvo DB. Intra-arterial cisplatin for patients with inoperable and skeletal tumors. *Cancer*, 48:1-4, 1981.
19. Mavligit GM, Calvo DB, Patt YZ, Hersh EM. Immune restoration and/or augmentation of local xenogenic graft versus host reaction by cimetidine in vitro. *Journal of Immunology*, 126: 2272-2274, 1981.
20. Tilchen E, Patt YZ, McBride CM, Wallace S, Chuang VP, Mavligit GM. Sequence of regional chemotherapy and surgery: Management of colorectal adenocarcinoma confined to the liver. *Archives of Surgery*, 116:959-960, 1981.
21. Chuang V, Wallace S, Benjamin RS, Jaffe N, Ayala A, Murray J, Zornoza J, Patt YZ, Mavligit GM, Charnsangavej C, Soo CS. The therapy of osteosarcoma by intra-arterial cisplatin and limb preservation. *Cardiovascular and Interventional Radiology*, 4:229-235, 1981.
22. Talpaz M, Medina JE, Patt YZ, Goepfert H, Guillaumondegui OM, Wong W, Mavligit GM. The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients. *Clinical Immunology and Immunopathology*, 24:155-160, 1982.

23. Bledin AG, Kantarjian HM, Kim EE, Wallace S, Chuang VP, Patt YZ, Haynie TP. Tc-labeled macroaggregated albumin in intrahepatic arterial chemotherapy. *American Journal of Roentgen*, 139:711-714, 1982.
24. Patt YZ, Peters RE, Chuang VP, Wallace S, Mavligit GM. Effective retreatment of patients with colorectal cancer and liver metastases. *American Journal of Medicine*, 75:237-240, 1983.
25. Patt YZ, Chuang VP, Wallace S, Benjamin RS, Fuqua R, Mavligit GM. Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. *Cancer*, 51:1359-1363, 1983.
26. Bedikian AY, Chen TT, Malahy MA, Patt YZ, Bodey GP. Prognostic factors influencing survival of patients with advanced colorectal cancer: Hepatic-artery infusion versus systemic intravenous chemotherapy for liver metastases. *Journal of Clinical Oncology*, 2:174-180, 1984.
27. Bedikian AY, Patt YZ, Murphy WK, Umsawasadi T, Carr DT, Hersh EM, Bodey GP, Valdivieso M. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy. *American Journal of Clinical Oncology*, 7:399-404, 1984.
28. Frost DB, Patt YZ, Mavligit GM, Chuang VP, Wallace S. Arterial infusion of DTIC and CDDP for recurrent regionally confined melanoma. *Archives of Surgery*, 120:478-480, 1985.
29. Patt YZ, Peters RE, Chuang VP, Wallace S, Fuqua R, Mavligit GM. Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-FU and mitomycin. *Cancer*, 56:2175-2180, 1985.
30. Carrasco CH, Wallace S, Charnsangavej C, Papadopoulos NEJ, Patt YZ, Mavligit GM. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. *JAMA*, 255:3152-3154, 1986.
31. Patt YZ, Mavligit GM, Reuben J, Mansell PWA, Li S, Newell G, Talpaz M, Hersh EM. Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon. *Journal of Biological Response Modifiers*, 5:263-269, 1986.
32. Patt YZ, Hersh EM, Reuben J, Claghorn L, Mavligit G. A phase I study of intravenous Azimexon therapy in human cancer. *Journal of Biological Response Modifiers*, 5:313-318, 1986.
33. Patt YZ, Mansell PWA, Reuben JM, Claghorn L, Li S, Gehan E, Hersh EM. Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS related complex (ARC). *AIDS Research*, 2:191-209, 1986.

34. Patt YZ, Boddie AW, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with 5-FUDR and CDDP: Overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. *Journal of Clinical Oncology*, 4:1356-1364, 1986.
35. Carrasco CH, Wallace S, Charnsangavej C, Papadopoulos NEJ, Patt YZ, Mavligit GM. Treatment of hepatic metastases in ocular melanoma: Embolization of the hepatic artery with polyvinyl sponge and cisplatin. *Journal of American Medical Association*, 255:3152-3154, 1986.
36. Patt YZ, McBride CM, Ames FC, Claghorn LJ, Cleary KR, Boddie AW, Charnsangavej C, Mavligit GM. Adjuvant perioperative hepatic arterial mitomycin-C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver. *Cancer*, 59:867-873, 1987.
37. Mavligit GM, Faintuch J, Levin B, Wallace S, Charnsangavej C, Carrasco C, Patt YZ. Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. *Gastroenterology*, 92:566-569, 1987.
38. Fraschini G, Fleishman G, Yap HY, Carrasco H, Charnsangavej C, Patt YZ, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. *Cancer Treatment Reports*, 71:313-315, 1987.
39. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM. Hepatocellular Carcinoma: A retrospective analysis of treatments to manage disease confined to the liver. *Cancer*, 61:1884-1888, 1988.
40. Patt YZ, Lamki LM, Haynie TP, Unger MW, Rosenblum MG, Shirkhoda A, Murray JL. Improved Tumor Localization with increasing dose of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. *Journal of Clinical Oncology*, 6:1220-1230, 1988.
41. Lamki LM, Patt YZ, Murray JL, Shanken LJ. The role of In-111 anti-CEA monoclonal antibody in the detection of occult metastatic cancer in patients with rising serum CEA. *Journal of Nuclear Medicine*, 29:833-834, 1988.
42. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. *Journal of the American Medical Association*, 260:974-976, 1988.
43. Lamki LM, Murray JL, Rosenblum MG, Patt YZ, Babaian R, Unger MW. Effect of unlabeled monoclonal antibody (MoAb) on biodistribution and pharmacokinetics of 111-Indium labeled MoAb. *Nuclear Medicine Communications*, 9:553-564, 1988.
44. Patt YZ, et al. Treatment of hepatocellular carcinoma with hepatic arterial floxuridine, doxorubicin and mitomycin (FUDRAM) with or without hepatic artery embolization: factors associated with longer survival. *Regional Cancer Treatment*, 2:98-104, 1989.

45. Mavligit GM, Patt YZ, Haynie, TP, Carrasco CH, Charnsangavej C and Wallace S. Differential tumor regression in patients with bilobar hepatic metastases and dual arterial supply, evidence supporting the advantage of intra-arterial over intravenous route of drug delivery. *Selective Cancer Therapeutics*, 5:37-45, 1989.
46. Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. *Cancer Invest*, 8:617-619, 1990.
47. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutter JU. A phase I trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. *Cancer Research*, 49:4057-4061, 1989.
48. Ajani JA, Ota DM, Grossie VB, JR., Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. *Cancer Chemother Pharmacol*, 26:223-226, 1990.
49. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium ¹¹¹-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody ZCE-025 CEAKER™ of recurrent colorectal or CEA producing cancer in patients with rising serum CEA levels and occult metastases. *J Clin Oncol*, 7:1246-1254, 1990.
50. Pazdur R. Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman JU, Levin B. Phase II study of fluorouracil and recombinant alpha-2a-interferon in previously untreated advanced colorectal carcinoma. *J Clin Oncol*, 8:2027-2031, 1990.
51. Lamki LM, Patt YZ, Rosenblum MG, Shanken LJ, Thompson LB, Schweighardt SA, Frincke JM, Murray JL. Metastatic colorectal cancer: Radioimmunoscinigraphy with a stabilized In-¹¹¹-labeled F(ab')₂ fragment of an anti-CEA monoclonal antibody. *Radiology*, 174:147-151, 1990.
52. Khardori N, Wong E, Carrasco CH, Wallace S, Patt YZ, Bodey GP. Infections associated with biliary drainage procedures in patients with cancer. *Reviews of Infectious Diseases*, 13:587-591, 1991.
53. Wong E, Khardori N, Carrasco CH, Wallace S, Patt YZ, Bodey GP. Infectious complications of hepatic artery catheterization procedures in patients with cancer. *Reviews of Infectious Diseases*, 13:583-586, 1991.
54. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. *Investigational New Drugs*, 9:369-371, 1991.

55. Ajani JA, Pazdur R, Winn RJ, Abbruzzese J, Levin B, Wiseman C, Llenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. *Invest New Drugs*, 9:257-260, 1991.
56. Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. *Investigational New Drugs*, 10:211-213, 1992.
57. Jones DV, Patt YZ. Regional therapy for metastatic liver disease. *Journal of Infusional Chemotherapy*, 2:115-123, 1992.
58. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. *Cancer*, 71:1214-1218, 1993.
59. Ajani JA, Abbruzzese JL, Markowitz A, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. *Investigational New Drugs*, 11:67-69, 1993.
60. Patt YZ, Podoloff DA, Curley S, Smith R, Bhadkamkar V, Lamki LM, Jessup MM, Hohn DC. Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen. *Cancer*, 71(12):4293-4297, 1993.
61. Charnsangavej C, Kirk IR, Dubrow RA, Chuang VP, Curley SA, Roh MS, Varma DGK, Patt YZ. Arterial complications from long-term hepatic artery chemoinfusion catheters: Evaluation with CT. *AJR*, 160:879-864, 1993.
62. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, Roh M, Smith R, Noonan C, Levin B. Low serum alpha-fetoprotein level in hepatocellular carcinoma patients as a predictor of response to 5FU and interferon-alfa-2b. *Cancer*, 72(9):2574-2582, 1993.
63. Jones Jr. DV, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. Phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. *Cancer*, 72(9):2560-2563, 1993.
64. Patt YZ, Podoloff DA, Curley S, Kasi K, Smith R, Bhadkamkar V, Charnsangavej C. Technetium 99m-Labeled IMMU-4: A monoclonal antibody against carcinoembryonic antigen for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. *J Clin Oncol*, 12(3):489-495, 1994.
65. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H, Jones D, Levin B. Hepatic arterial infusion of floxuridine, leucovorin, adriamycin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. *J Clin Oncol*, 12(6):1204-1211, 1994.

66. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt YZ, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. *Annals of Oncology*, 5:468-470, 1994.
67. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B, Levin B. Phase II trial of UFT plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. *J Clin Oncol*, 12:2296-2300, 1994.
68. Jones DV Jr, Sugarman SM, Markowitz A, Levin B, Abbruzzese JL, Evans DB, Charnsangavej, Smith R, Patt YZ. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. *Oncology Reports*, 2:1121-1123, 1995.
69. Jones Jr DV, Chase J, Roh M, Hohn D, Curley S, Smith R, Patt YZ. A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer. *International Journal of Oncology*, 3:391-395, 1996.
70. Moffat Jr FL, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM, the Immunomedics Study Group. Clinical utility of external immunoscintigraphy with the IMMU-4^{99m}Tc-Fab¹ antibody fragment (CEA-Scan; arcitumomab) in patients undergoing surgery for carcinoma of the colon and rectum. *Journal of Clinical Oncology*, 14(8):2295-2305, 1996.
71. Patt YZ, Jones Jr DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous 5-fluorouracil and subcutaneous interferon alpha 2b for biliary tree cancer. *Journal of Clinical Oncology*, 14(8):2311-2315, 1996.
72. Jones Jr DV, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. *Journal of Clinical Oncology*, 14(8):2306-2310, 1996.
73. Davidson BS, Izzo Francesco, Chase JL, DuBrow RA, Patt YZ, Hohn DC, Curley SA. Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. *The American Journal of Surgery*, 172:224-247, 1996.
74. Hammoud MA, McCutcheon IE, Elsouki R, Schoppa D, Patt YZ. Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. *Annals of Surgical Oncology*, 3(5): 453-463, 1996.
75. Sirisriro R, Podoloff DA, Patt YZ, Curley SA, Kasi LP, Bhadkamkar VA, Kim EE, Murray JL, Smith R, Haynie TP. TC-99 (M) -IMMU4 imaging in recurrent colorectal cancer - efficacy and impact on surgical management. *Nuclear Medicine Communications*, 17(7):568-576, 1996.

76. Hughes K, Pinsky CM, Petrelli NJ, Moffat FL, Patt YZ, Hammershaimb L, Goldenberg DM. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. *Annals of Surgery*, 226(5):621-631, 1997.
77. Patt YZ, Hoque A, Lozano R, Pazdur R, Chase J, Carrasco H, Chuang V, Deslpassand ES, Ellis L, Curley S, Roh M, Jones Jr DV. Phase II trial of hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) and recombinant human interferon 2b (rIFN2b) for liver metastases of colorectal cancer (CRC) refractory to systemic 5-FU and leucovorin. *Journal of Clinical Oncology*, 15:1432-1438, 1997.
78. Wu X, Gu J, Patt YZ, Hassan M, Spitz MR, Beasley RP, Hwang LY. Mutagen Sensitivity as a Susceptibility Marker for Human Hepatocellular Carcinoma. *Cancer Epidemiol Biomark. Prev*, 7:567-570, 1998.
79. Pawarolde A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. *Am J of Clin Oncol*, 21 (4):386-391, 1998.
80. Ajani, J. Fairweather, J. Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II Study of Taxol patients with advanced gastric carcinoma. *Cancer J Sci Am*, 4(4):269-274, 1998.
81. Patt YZ, Hoque A, Roh M, Ellis L, Lozano R, Carrasco CH, Charnsangavej C, and Cleary K. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinum, recombinant interferon γ 2B, doxorubicin, and 5-fluorouracil. *Am J of Clin Oncol*, 22(2):209-213, 1999.
82. Leung TWT, Patt YZ, Wan-ye L, Ho SKW, Simon CHY, Chan ATC, Mok TSK, Yeo W. Liew C, Leung NWY, Tang AMY, Johnson PJ. Complete pathological Remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. *Clin Ca Res*, 5: 1676-1681, 1999.
83. Hoque A, Patt YZ, Yoffe, B, Groopman, JD, Greenblatt MS, Zhang YJ, Santella RM. Does Aflatoxin B₁ play a role in the etiology of hepatocellular carcinoma in the United States? *Nutrition and Cancer*, 35(1):27-33, 1999.
84. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA Case Report. Durable Clinical Response of Refractory Hepatocellular Carcinoma to Orally Administered Thalidomide. *Am J Clin Oncol (CCT)*, 23(3):319-321, 2000.
85. Meric F, Patt YZ, Curley S, Chase J, PharmD, Roh MS, Vauthey JN, Ellis LM. Surgery after Downstaging of Unresectable Hepatic Tumors with Intra-Arterial Chemotherapy. *Ann of Surg Oncol*, 7(7):49-495, 2000.
86. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappel CL, Beasley, RP, and Hwang L. The role of hepatitis C in hepatocellular carcinoma. A case control study among egyptian patients. *J Clin Gastroenterol*, 33(2):123-126, 2001.

87. Patt YZ, Hassan MM, Lozano RD, Waugh KH, Hoque AM , Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, and Raijman I . Phase II trial of cisplatin interferon alfa-2b, doxorubicin and 5-fluorouracil for biliary tract cancer. *Clinical Cancer Research*, 7(11):3375-3380, 2001.
88. Hassan M, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese J, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. *Hepatology* 36(5) 1206-1213, 2002.
89. Hassan M, El-Serag H, Frome A, Patt YZ. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. *J Clin Gastroenterol* 35(5):1206-1213, 2002.
90. Patt YZ, Hassan M, Lozano R, Vauthey J, Curley S, Ellis L. Phase II trial of systemic continuous 5-FU and subcutaneous rINF α 2b for treatment of hepatocellular carcinoma. *J Clin Oncol*, 21:421-427, 2003.
91. Ghalib R, Hassan M, Levine CH, McClelland T, Goss J, Stribling R, Seu PH, Patt YZ. The effect of recombinant human interleukin-11 (Neumega) on thrombocytopenia induced by cirrhosis. *Hepatology*, 37: 1165-1171, 2003.
92. Scaife CL, Curley SA, Izzo F, Marra P, Delrio P, Daniele B, Cremona F, Gershenwald JE, Chase JL, Lozano RD, Patt YZ, Fornage BD, Vauthey JN, Woodall ML, Gonzales KB and Ellis LM. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with metastases from colorectal cancer. *Annals of Surgical Oncology* 10: 348-354, 2003.
93. Cusnir M, & Patt YZ . Novel systemic therapies for Hepatocellular carcinoma. *Cancer J*;10: 97-103,2004.
94. Patt YZ, Hassan MM, Aguayo A, Nooka AJ Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolf RA, Charnsangavej C, Brown TD. Oral Capecitabine (Xeloda®) for Hepatocellular Carcinoma, Cholangiocarcinoma and Gallbladder Cancer. *Cancer* 101:578-586, 2004
95. Patt YZ, Hassan MM, Nooka A, Lozano R, Schnirer I, Zeldis J, Abbruzzese J, Brown T. Thalidomide in the treatment of patients with hepatocellular carcinoma (HCC): a phase II trial. *Cancer* 103:749-755, 2005
96. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey JN, Cornelis M, and Kahan JP. OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer. *Journal of Clinical Oncology* 23: 7125-7134, 2005

97. Abou-Alfa, GK; Rowinsky, EK; **Patt, YZ**; Schwartz, GK; Kelsen, DP; Sharma, S; Siegel, E; Becerra, CR ; Eckhardt, SG ; Feit, K ; De Jager, R ; O'Reilly ; EM : A Phase II Study of Intravenous Exatecan Administered Daily for Five Days, Every Three Weeks to Patients with Biliary Tract Cancers. Am J Clin Oncol. 2005 Aug;28(4):334-9.

Journal Articles (Non-Refereed)

1. Patt YZ, Hersh EM, Abegbite M, Goldman R, Mavligit GM. New approaches to the valuation of immuno-modulation by thymic hormones. *Annals of the New York Academy of Sciences*, 332: 160-171, 1979.
2. Johnston S, Patt YZ. Caring for the patient on intra-arterial chemotherapy-Are you ready? *Nursing*, 81:108-112, 1981.
3. Patt YZ. Immunomodulation with thymic hormones in neoplastic disorders. *The Cancer Bulletin*, 33:265-271, 1981.
4. Patt YZ. Hepatic arterial chemotherapy for treatment and prophylactic of liver metastasis from colon cancer. *Cancer Bulletin*, 36:21-26, 1984.
5. Patt YZ. Hepatic arterial infusion of Floxuridine, Adriamycin and Mitomycin C for primary liver neoplasms. *Cancer Bulletin*, 36:29-31, 1984.
6. Patt YZ. Bilateral iliac artery infusion of 5-FU and mitomycin C for pelvic recurrence of colorectal cancer. *Cancer Bulletin*, 36:56-57, 1984.
7. Patt YZ, Murray JL, Lamki K. Indium-111 Anti Carcinoembryonic antigen (CEA) ZCE-025 in detection of metastatic colorectal cancer. *Cancer Bulletin*, 40:218-221, 1988.
8. Patt YZ, Mavligit GM. Arterial chemotherapy in the management of colorectal cancer: An overview. *Seminars in Oncology*, 18:478-490, 1991.
9. Patt YZ. RadioActive ImmunoDiagnosis (RAID) in patients with colorectal cancer and rising serum CEA. *New Perspectives in Cancer Diagnosis and Management*, 1(2):33-39, 1993.
10. Podoloff DA, Patt YZ, Curley SA, Kim EE, Bhadkamkar VA, Smith RE. Imaging of colorectal carcinoma with technetium-99m radiolabelled Fab' fragments. *Seminars in Nuclear Medicine*, 23 (2):89-98, 1993.
11. Jones Jr. DV, and Patt YZ. Treatment of hepatocellular carcinoma. *New Perspectives in Cancer Diagnosis and Management*, 3(1):14-23, 1995.
12. Patt YZ. Critique on the paper by Alan P. Venook. Regional strategies for managing hepatocellular carcinoma. *Oncology*, 14(3):347-54; discussion 354, 359, 363-364, 2000.
13. Aguayo A., and Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. *Clin Liver Dis*, 5(1): 175-189, 2001.
14. Aguayo, A, and Patt YZ. Liver Cancer. *Clin. Liver Dis*, 5(2): 479-501, 2001.

Abstracts (recent):

1. Patt YZ, Halabi S, Yoffe B, Smith R, Fischer H, Levin B, Spitz M. Ethnic differences in HBV and HCV serology among hepatocellular carcinoma (HCC) patients. *American Association for Cancer Research*, 35:1712, 1994.
2. Markowitz A, Thielvoldt D, Patt YZ, Sugarman S, Jones D, Pazdur R, Abbruzzese J, Levin B. Prolonged continuous intravenous infusion (CIV) fluorouracil (5-FU) plus daily subcutaneous (sc) interferon 2b (IFN) has activity in patients (pts) with colorectal cancer (CRC) who have failed prior 5-FU: Results of a phase I-II study. *American Society of Clinical Oncology*, 13:682, 1994.
3. Patt YZ, Jones D, Chase J, Charnsangavej C, Chuang V, Carrasco H, Lawrence D, Roh M. Hepatic arterial infusion (HAI) of recombinant interferon-alpha (rIFN) and 5-fluorouracil (5FU) for colorectal cancer (CRC) liver metastases refractory to intravenous (IV) 5FU and leucovorin (LCV). *American Society of Clinical Oncology*, 13:591, 1994.
4. Jones DV Jr, Sugarman S, Markowitz A, Levin B, Abbruzzese JL, Kuo MT, Patt YZ. A phase I-II study of amiodarone and doxorubicin for patients with advanced colorectal cancer. *American Society of Clinical Oncology*, 13:688, 1994.
5. Pazdur R, Lassere Y, Bready B, Soh L, Soo E, Ajani JA, Sugarman S, Patt YZ, Abbruzzese JL, Raber MN. Phase II trial of docetaxel in metastatic colorectal carcinoma. *8th NCI-EORTC Symposium*, 1994.
6. Pazdur R, Lassere Y, Bready B, Rhodes V, Soo E, Ajani JA, Abbruzzese JL, Patt YZ, Sugarman S, Levin B. Phase II clinical trial of UFT plus oral folinic acid: A potentially effective oral treatment regimen for metastatic colorectal carcinoma. *8th NCI-EORTC Symposium*, 1994.
7. Pazdur R, Rhodes V, Lassere Y, Bready B, Soo E, Ajani JA, Abbruzzese JL, Sugarman S, Jones D, Markowitz A, Patt YZ, Ho D, Levin B. UFT plus leucovorin: A potentially effective oral regimen in colorectal carcinoma. *American Society of Clinical Oncology*, 13:590, 1994.
8. Soh L, Pazdur R, Lassere Y, Bready B, Soo E, Sugarman S, Patt YZ, Abbruzzese J, Levin B. Phase II trial of docetaxel (Taxotere) in advanced colorectal carcinoma. *American Association for Cancer Research*, 35:1372, 1994.
9. Patt YZ, Hoque A, Podoloff DA, Pinsky CM, Goldenberg DM, Immunomedics Research Group, Immunomedics, Inc. CEA-Scan, a ^{99m}Tc-Labeled Fab fragment of MoAb Anti-CEA IMMU-4 for radioimmunodetection (RAID) of occult metastatic colorectal cancer (CRC) in patients (pts.) with rising serum CEA: A multi-institutional study.
10. Patt YZ, Hoque A, Lozano R, Curley S, Ellis L, Cleary K, Waugh K, Charnsangavej C. Systemic therapy with platinol, interferon α 2b, doxorubicin and 5-fluorouracil (5-FU) (PIAF) for treatment of non-resectable hepatocellular carcinoma (HCC). *Proceedings ASCO*, 17:301a (Abst 1158), 1998.

11. Leung WT, Patt YZ, Mok TSK, Lau WY, Ho SKW, Chan ATC, Yeo, W, Johnson PJ. Phase II study of cisplatin, doxorubicin, 5-fluorouracil and alpha-interferon for advanced hepatocellular carcinoma. *Proceedings ASCO*, 17:267a (Abst 1025), 1998.
12. Lozano R, Patt YZ, Ellis L, Hassan M, Chase J, Phan L, Vauthey JN, Curley S, Abbruzzese J, Wolff R, Brown T. A phase II trial of a hepatic arterial infusion (HAI) of platinol (CDDP), recombinant human interferon alpha-2B (rIFN α), adriamycin[®] (dox), and 5-FU (PIAF) for the treatment of hepatocellular carcinoma (HCC). *Proceedings ASCO*, 20:167a (Abst.666), 2001.
13. Patt YZ, Lozano R, Hassan M, Phan L, Ellis L, Vauthey JN, Curley S, Abbruzzese J, Wolff R, Brown T, Charnsangavej C. Continuous I.V. Infusion of 5-Fluorouracil (5-FU) and subcutaneous recombinant interferon alpha 2b (rIFN α 2b) is an active regimen in hepatocellular carcinoma. *Proceedings ASCO*, 20:168a (Abst. 671), 2001.
14. LI D, Hassan M, Chang P, Zhu J, Schwartz M, Ghalib R, Gudena V, Abbruzzese J, Patt Y. Increased oxidative DNA damage in HCV and alcohol- related liver cirrhosis and hepatocellular carcinoma. *Proceedings AACR*, 43:573 (Abst.2841), 2002.
15. Hassan M, Zhang W, Zhu J, Patt Y, Swaim M, Schwartz M, Ghalib R, Gudena V, Abbruzzese JL, Li D. Glutathione peroxidase and GSH/GSSG in hepatocellular carcinoma and cirrhosis in relation to HCV and alcohol. *Proceedings AACR*, 43:868 (Abst. 4299), 2002.

Books & Book Chapters

1. Hersh EM, Gutterman JU, Mavligit GM, Granatek CH, Rossen RD, Rios A, Goldstein AL, Patt YZ, Rivera E, Richman SP, Bottino J, Farquhar D, Morris D, Ezaki K. Clinical rationale for immunotherapy and its role in cancer treatment, In: *Immuno-therapy of Human Cancer*. New York: Raven Press, 83-97, 1978.
2. Patt YZ, Hersh EM, Schafer LA, Heilbrun LK, Washington ML, Gutterman JU, Mavligit GM, Goldstein AL. Clinical and immunological evaluation of the use of thymosin plus BCG + DTIC in the adjuvant treatment of stage 3B melanoma. In: Chirigos MA (Ed.), *Immune Modulation and Control of Neoplasia by Adjuvant Therapy*. New York: Raven Press, 357-371, 1978.
3. Hersh EM, Patt YZ, Mavligit GM, Murphy SG, Gutterman JU, Dicke K, Spitzer G. Studies of cell mediated immunity in man and the effects of immunotherapy. In: Human lymphocyte differentiation: Its Application to Cancer. International Symposium on Human Lymphocyte Differentiation. Serrou B, Rosenfield C (eds). Elsevier/North Holland Biomedical Press, 375-382, 1978.
4. Patt YZ, Calvo DB, Benjamin RS, Mavligit GM. Treatment of regionally confined metastatic tumor with arterial infusion of cisplatin, In: Prestayko AW, Cooke ST, Carter SK (Eds.), *The Third Annual Symposium on Cisplatin Current and New Developments*. New York: Academic Press, Inc., 37:495-509, 1980.

5. Hersh EM, Patt YZ, Gutterman JU, Murphy S, Mavligit GM, Richman SP, Moroun J, Lotzova E, Dicke K, Zander A. Host defense mechanisms in cancer and their modification by immunotherapy. In: Crispen E (Ed.), *Neoplasm Immunity. Experimental and Clinical*. Elsevier North Holland, Inc., 247-264, 1980.
6. Bedikian AY, Bodey GP, Valdivieso M, Stroehlein JR, Karlin DA, Bennetts RW, Patt YZ, Burgess MA. Chemotherapeutic management of colorectal cancer and prospects for new agents. In: Stroehlein JR, Romsdahl MM (Eds.), *Gastrointestinal Cancer*. New York: Raven Press, 365-379, 1981.
7. Patt YZ, Bedikian AY, Chuang VP, Wallace S, Fuqua R, Mavligit GM. New approaches to the treatment of Dukes' C colorectal carcinoma and to metastatic colorectal carcinoma confined to the liver. In: Stroehlein JR, Romsdahl MM (Eds.), *Gastrointestinal Cancer*. New York: Raven Press, 391-403, 1981.
8. Patt YZ, Charnsangavej C, Soski M, Mavligit GM. Regional arterial therapy in the management of primary liver neoplasms. In: Bottino JC, Opfell R, Muggia F (Eds.), *Liver Cancer*. Boston: Martinus Nijhoff Publishers, 263-273, 1985.
9. Patt YZ, Charnsangavej C, Boddie A, Mavligit GM, Soski M, Wallace S. Regional arterial chemotherapy or arterial embolization in the management of various stages of colon cancer. In: Bottino JC, Opfell R, Muggia F (Eds.), *Liver Cancer*. Martinus Nijhoff Publishers, 341-355, 1985.
10. Patt YZ, Charnsangavej C, Soski M. Hepatic arterial infusion of floxuridine, Adriamycin, and mitomycin C for primary liver neoplasms. In: Howell SB (Ed.), *Intra-arterial and Intracavitary Chemotherapy*. Martinus Nijhoff Publishers, 125-140, 1985.
11. Patt YZ, Ajani J, Boddie A, Charnsangavej C, Claghorn L, Soski M. Arterial cisplatin and floxuridine for colorectal cancer metastatic to the liver. In: Ishigami J (Ed.), *Recent Advances in Chemotherapy*. Kyoto: University of Tokyo Press, 1168-1169, 1985.
12. Patt YZ, Boddie A, Soski M, Claghorn L. Arterial Therapy: Percutaneous catheters or implantable infusion devices (Medtronic DADS, Infusaid). In: Ensminger WD, Selam JL (Eds.), *Infusion Systems in Medicine*. Mount Kisco, NY: Futura Publishing Co., Inc., 189-199, 1988.
13. Patt YZ, Boddie A, Charnsangavej C, Mavligit GM, Cleary K, Soski M, Claghorn L, Wallace S. Arterial therapy in the management of resectable and non-resectable metastatic colorectal cancer in the liver. In: Aigner KR, Patt YZ, Link KH, Kreidler J (Eds), *Regional Cancer Treatment. Contributions to Oncology*. Basel: Karger, 205-216, 1988.
14. Boddie AW, Patt YZ, McBride CM, Wallace S, Ajani AJ, Charnsangavej C, Soski M, Levin B. MDAH surgical experience with the implantable Infusaid Pumps and Medtronic drug

administration devices. In: Aigner KR, Patt YZ, Link KH, Kreidler J (Eds.), *Regional Cancer Treatment. Contributions to Oncology*. Basel: Karger, 193-204, 1988.

15. Patt YZ, Charnsangavej C, Soski M, Claghorn L. Bilateral iliac artery infusion of 5-FU and mitomycin for palliation of pelvic recurrence of colorectal cancer. In: Levin B (Ed.), *Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment*. University of Texas Press, 30:225-229, 1988.
16. Patt YZ. Hepatic arterial infusion (HAI) of chemotherapy for metastatic colorectal cancer to the liver: Why, How and What. In: . H. Schonfeld (Ed.), *Regional Chemotherapy. Antibiotics and Chemotherapy*. Basel: Karger, 40:1-11, 1988.
17. Patt YZ. *Hepatic arterial chemotherapy for liver neoplasms: Where do we go now?* Ensminger WD, Selam JL (Eds.): Futura Publishing, 1989.
18. Lamki LM, Patt YZ, Murray JL. In-¹¹¹ monoclonal antibody immunoscintigraphy of colorectal cancer. In: Goldenberg DM (Ed.), *Cancer Imaging With Radiolabeled Antibodies*. Boston: Martinus Nijhoff Publishing, 293-312, 1989.
19. Boddie AW, Patt YZ. Implantable pumps for hepatic metastases. In: Economou SG, Witt TR, Deziel DJ, Saclarides TJ, Staren ED, Bines SD (Eds.), *Adjuncts to Cancer Surgery*. Philadelphia & London: Lea & Febiger, 414-418, 1991.
20. Jones Jr DV, Patt YZ. Regionale therapie hepatischer tumoren. In: *Therapie-Konzepte Onkologie*. Berlin: Schutte, Springer – Verlag, 594-625, 1995.
21. Jones Jr DV, Hogue A, Patt YZ. Regionale therapie hepatischer tumoren. In: *Therapie-Konzepte Onkologie*. Berlin: Schutte, Springer – Verlag, 712-747, 1998.
22. Patt YZ, Hoque A. Multi-modal Treatment of Liver Neoplasms. In: Clavien PA (Ed.), *Malignant Liver Tumors: Current and Emerging Therapies*. Massachusetts: Blackwell Science, 198-211, 1999.
23. Hassan M, Patt YZ, Hepatocellular Cancer: Epidemiology and Molecular Epidemiology of Hepatocellular Cancer. In: Abbruzzese JL, Evans DB, Willet C, Hamilton S (Eds.), *The Principles and Practice of Gastrointestinal Oncology*. Oxford University Press, in press.
24. Patt YZ, Hassan M. Hepatocellular Cancer: Clinical Aspects and Management of Hepatocellular Cancer. In: Abbruzzese JL, Evans DB, Willet C, Hamilton S (Eds.), *The Principles and Practice of Gastrointestinal Oncology*. Oxford University Press, 2003

Letters to the Editor/Editorials:

1. Jones DV Jr, Lawrence DD, Patt YZ. Percutaneous transcatheter arterial embolization for hypersplensim. Letter to the Editor. *Annals of Internal Medicine*,123(10):810-11, 1995.

2. Patt YZ. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues. Editorial. *J Clin Oncol*, 11(5):815-819, 1993.
3. Patt YZ. More on hepatic arterial therapy. Letter to the Editor. *J Clin Oncol*, 11: 2053-2054, 1993.
4. Patt YZ. Hepatocellular carcinoma: Prevention is the best cure. Editorial. *New Perspectives in Cancer Diagnosis and Management*, 3(1):1-2, 1995.

Major Invited Speeches or Talks:

1. Patt YZ, *Hepatocellular Cancer in North America*, Beijing, Peoples Republic of China, 1985.
2. Patt YZ, *Pros and Cons in Regional Arterial Therapy*, Swiss Society of Oncology, Bern, Switzerland, 1986.
3. Patt YZ, *Arterial Treatment of HCC*, International Congress on Gastroenterology, Jerusalem, Israel, 1989.
4. Patt YZ, *Regional Arterial Therapy of Liver Metastases from Colon Cancer: Perspectives for the 90's*, 34th Annual Meeting of the German and Austrian Society of Oncology, Hanover, West Germany, 1989.
5. Patt YZ, *Treatment of HCC with IV 5FU and S.C. rIFN-alpha*, National Conference on HCC in North America, NCI, Bethesda, Maryland, 1990.
6. Patt YZ, *Perspectives on Regional Cancer Treatment*, 3rd International Conference on Neoadjuvant Therapy, Session Chairman: Regional Arterial Therapy, Paris, France, 1991.
7. Patt YZ, *Management of Primary and Metastatic Liver Neoplasms*, Arizona Cancer Center, Grand Rounds, Tucson, Arizona, 1991.
8. Patt YZ, *Etiology and Treatment of Hepatocellular Cancer*, M.D. Anderson Cancer Center, Grand Rounds, Houston, Texas, 1991.
9. Patt YZ, *Viral Etiologies in North American HCC*, Chulalongkorn Hospital, Bangkok, Thailand 1991.
10. Patt YZ, *Treatment Options for HCC*, Chiangmai University Hospital, Chiangmai, Thailand, 1991.
11. Patt YZ, *Role of MoAb Imaging in Management of Colon Cancer*, Ben Gurion University, Soroka Medical Center, Beer Sheva, Israel, 1991.

12. Patt YZ, *Viral Etiology and Therapy of Hepatocellular Cancer*, Ben Gurion University, Soroka Medical Center, Beer Sheva, Israel, 1991.
13. Patt YZ, *Viral Etiologies in North American HCC*, 29th Annual Congress of Japan Society for Cancer Therapy and International Conference on Regional Chemotherapy for Liver Cancer, Session Chairman on Hepatocellular Cancer, Osaka, Japan, 1991.
14. Patt YZ, *Treatment Options for HCC*, 29th Annual Congress of Japan Society for Cancer Therapy and International Conference on Regional Chemotherapy for Liver Cancer, Session Chairman on Hepatocellular Cancer, Osaka, Japan, 1991.
15. Patt YZ, *Innovative Approaches to Treatment of Primary and Metastatic Liver Neoplasms*, Hospital de la Cruce Roja, Barcelona, Spain, 1991.
16. Patt YZ, *Role of Monoclonal Antibody Imaging in Colorectal Cancer*, American Cancer Society, Atlanta, Georgia, 1992.
17. Patt YZ, *Hepatocellular Cancer: Etiology, Biology and Treatment Options*, St. Louis University Medical Center, St. Louis, Missouri, 1992.
18. Patt YZ, *Etiology, Biology and Treatment of Hepatocellular Cancer*, The Albert Einstein Hospital and the University of Sao Paulo, Sao Paulo, Brazil, 1992.
19. Patt YZ, *Treatment of Liver Metastasis in Colon Cancer*, The Albert Einstein Hospital and the University of Sao Paulo, Sao Paulo, Brazil, 1992.
20. Patt YZ, *Use of Imaging with Monoclonal Antibodies in Colon Cancer*, The Albert Einstein Hospital and the University of Sao Paulo, Sao Paulo, Brazil, 1992.
21. Patt YZ, *Hepatocellular Cancer: Etiology and Treatment*, University of Southern California, Los Angeles, California, 1993.
22. Patt YZ, *Hepatocellular Cancer*, Bolivian Academy of Medicine, La Paz, Bolivia, 1993.
23. Patt YZ, *Etiology and Therapeutic Options*, Bolivian Academy of Medicine, La Paz, Bolivia, 1993.
24. Patt YZ, *Monoclonal Antibody: Diagnosis of Colon Cancer*, Bolivian Academy of Medicine, La Paz, Bolivia, 1993.
25. Patt YZ, *Hepatic Arterial Infusion of Recombinant Interferon Alpha: A New Approach to the Therapy of Colon Cancer and Hepatoma in the Liver*, 7th European Conference of Clinical Oncology and Cancer Nursing (ECCO 7), Chairman: Meet the Professor Session, Jerusalem, Israel, 1993.
26. Patt YZ, *Etiology and Treatment of Hepatocellular Cancer*, G.I. Research Forum, Texas Medical Center, Houston, Texas, 1993.

27. Patt YZ, *Etiologic Factors and Therapeutic Options in Hepatobiliary Tumors*, Menofia University and Tanta Cancer Institute, Visiting Professor, Egypt, April 1995.
28. Patt YZ, *IFN and Chemotherapy (PIAF) for Hepatobiliary Tumors*, Chulalongkorn University Bangkok, Visiting Professor, Thailand, July 1995.
29. Patt YZ, *The Future of Regional Hepatic Artery Therapy*, Keynote Address to German and Swiss Society for Research on Liver Tumor, Johann Wolfgang Goethe University, Frankfurt, Germany, December 1995.
30. Patt YZ, *Hepatobiliary Tumors: Rational and Clinical Application of HAI and Systemic Chemotherapy in Combination with Recombinant Interferon Alpha (PIAF)*, Presentation to Intron-A Oncology Advisory Board Meeting for Schering-Plough, Inc., New York City, NY, January 1996.
31. Patt YZ, *Hepatobiliary Cancers*, Presentation at Ground Rounds, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, February 1996.
32. Patt YZ, *CEA-Scan*, Presentation to the Federal Drug Administration for Immunomedics, Inc., February 1996.
33. Patt YZ, *Address: Viral and Molecular Correlates of HCC in the U.S., Panel: Therapeutic Options for Hepatocellular Carcinoma: Regional and Systemic Approaches*, Address and Panel Discussion at the Shanghai International Symposium on Liver Cancer & Hepatitis Shanghai, Peoples' Republic of China, March 1996.
34. Patt YZ, *PIAF (ID 95-126) Protocol and M.D. Anderson Cancer Center Current Management Algorithm*, Hepatoma Workshop at the Chinese University of Hong Kong, March 1996.
35. Patt YZ, *Molecular Epidemiology of Hepatocellular Carcinoma and Viral Hepatitis in the United States*, Address at the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, March 1996.
36. Patt YZ, *Hepatobiliary Cancer: Viral and molecular Epidemiology in the US, novel and therapeutic approaches*, Presentation to the Eastern Cooperative Oncology Group (ECOG), Baltimore, MD, April 1996.
37. Patt YZ, *Hepatobiliary Cancer: Insights into etiology & innovative therapeutic approaches* Presentation at Grand Rounds, Emory University, Atlanta, Georgia, May 1996.
38. Patt YZ, *Hepatitis C and Hepatocellular Cancer: Novel Regional and Systemic Treatment Approaches*, Presentation at the INTRON A/Hepatitis V1th Annual Speakers Update Meeting Schering Oncology/Biotech Marketing Group, June 1996.
39. Patt YZ, *Viral and Molecular Correlates of Hepatocellular Carcinoma in the United States, and Therapeutic Approaches to Hepatobiliary Cancers*, High Country Meeting, Vail, Colorado, June 1997.

40. Patt YZ, *Does Aflatoxin (AFB₁) Play a Role in the Etiology of Hepatocellular Carcinoma (HCC) in the United States (U.S.)*, Presentation at Annual Meeting, American Society of Clinical Oncology, Colorado Convention Center, Denver, Colorado, May 1997.
41. Patt YZ, *Symposium on Chemobiotherapy of Hepatoma and Cholangioma*, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, June 1997.
42. Patt YZ, *Symposium on Chemobiotherapy of Hepatoma and Cholangioma*, Chinese University of Hong Kong, Queen Mary Hospital, Hong Kong, June 1997.
43. Patt YZ, *PIAF Bio-Chemotherapy for HCC* Hong Kong University, Queen Mary Hospital, June 1997.
44. Patt YZ, *PIAF Regimen in Hepatocellular Carcinoma*, Lecturer for 1997 Oncology Fellowship Program, and Participant in Symposium on "Chemobiotherapy of Hepatoma and Cholangioma, Thailand, Medical Oncology Unit, Department of Medicine, Chulalongkorn University, June 1997 – July 1997.
45. Patt YZ, *Regional Chemotherapy in Colorectal Cancer*, 10th Brazilian Congress on Clinical Oncology, Sao Paulo, Brasil, August 1997.
46. Patt YZ, *Hepatobiliary Cancer: Insights into Etiology and Innovative Therapeutic Approaches*, "Meet the Professor" Session, 10th Brazilian Congress on Clinical Oncology, Sao Paulo, Brasil, August 1997.
47. Patt YZ, *Etiologic Factors and Treatment Options in Hepatobiliary Cancer*, University Federal do Rio Grande do Sul, Porto Alegre, Brasil RS, Rua Ramiro Barcelos 2350, August 1997.
48. Patt YZ, *Hepatocellular Carcinoma: Etiologic Factors and Novel Therapeutic Options*, Egyptian Congress of Medical Oncology, Cairo, Egypt, October 1997.
49. Patt YZ, *Treatment of Hepato-Biliary Cancer: A Therapeutic Challenge*, International Conference on Pancreatic and Hepatobiliary Cancer, Aegean University, Izmin, Turkey, November 1997.
50. Patt YZ, *Scientific Advisor and Presenter: 1) Treatment Options for HCC 2) Discussion Moderator: The Potential for Prevention of HCC in Cirrhotic Patients with HCV Infection*, The First Annual International Conference On: diagnosis and Treatment of Hepatic Neoplasms, New York University Post Graduate Medical School, New York, November 1997.
51. Patt YZ, *Hepatocellular Carcinoma (HCC): Epidemiology, Prevention and Treatment Options*, Grand Rounds, M.D. Anderson Cancer Center University of Texas, Houston, Texas, January 1999.

52. Patt YZ, *Hepatocellular Carcinoma: The Role of Angiogenesis and Angiogenesis Inhibitor*, Grand Rounds, Methodist Hospital and Baylor College of Medicine, Houston, Texas, August 1999.
53. Patt YZ, *Hepatocellular Carcinoma: Can The Rising Tide Be Stemmed?*, M.D. Anderson Cancer Center, Grand Rounds, Houston, Texas, 1999.
54. Patt YZ, *Multidisciplinary Approach to the Treatment of Hepatocellular Carcinoma*, International Symposium Controversies in the Treatment of Hepatocarcinoma, Pordenon, Italy, October 1999.
55. Patt YZ, *Hepatobiliary and Colon Cancer and the Role of Xeloda in Treatment*, Hillcrest Baptist Medical Center, Waco, Texas, November 1999.
56. Patt YZ, *A How To in Maui: A Practical Approach to Gastrointestinal, Pancreatobiliary and Hepatic Disease* Conference, Maui, Hawaii, February 2000.
57. Patt YZ, *Challenges and Therapeutic Options in Colorectal and Hepatobiliary Carcinoma*, Multidisciplinary Conference and Colorectal Cancer Seminar, Istanbul, Turkey, February 2000.
58. Patt YZ, *Liver Cancer with Chronic Hepatitis*, College Station Medical Center, College Station, Texas, March 2000.
59. Patt YZ, *Challenges and Therapeutic Options in Colorectal and Hepatobiliary Malignancies*, Medical Grand Rounds, Roswell Park Cancer Institute, Buffalo, New York, March 2000.
60. Patt YZ, *International Symposium Liver Cancer: A Global Concern*, American Society of Clinical Oncology 36th Annual Meeting, New Orleans, Louisiana, May 2000.
61. Patt YZ, *Hepatocellular Carcinoma: Epidemiology and the Potential Preventative and Therapeutic Role in Angiogenesis Inhibitors*, Grand Rounds, Washington Hospital Center/Cancer Institute, Washington, DC, August 2000.
62. Patt YZ, *Liver Cancer: Future Trends*, 4th Shanghai International Symposium on Liver Cancer and Hepatitis, Pundong, Shanghai, September 2000.
63. Patt YZ, *European School of Oncology – Recent Advances in Colorectal Carcinoma*, Ankara, Turkey, November 2000.
64. Patt YZ, *Colorectal Cancer: Current Strategies Future Trends*, Faculty member at a Department of Veteran Affairs satellite videoconference launched by the South Central VA Healthcare network educational initiative. Birmingham, Alabama, March 2001.
65. Patt YZ, *New Developments in Hepatobiliary Cancer*, Southern California Association of Clinical Oncology (SCACO) Annual Meeting, Newport Beach, CA, April 2001.

66. Patt YZ, *Treatment of Liver Metastases from Colon Cancer*, Alegent Omaha Nebraska Health Medical Staff, Omaha, Nebraska, May 2001.
67. Patt YZ, *Launching of a National Multi-Institutional Study of Capecitabine and CPT-11 for Metastatic Colorectal Cancer*, New York, NY, August 2001.
68. Patt YZ, *New Opportunities in the Management of Metastatic Colon Cancer*, Chilean Society of Internal Medicine, Santiago, Chile, October 29, 2002.
69. Patt YZ, *Epidemiology, Prevention and Treatment of Hepatocellular Carcinoma*, Chilean Society of Internal Medicine, Santiago, Chile, October 30, 2002.
70. Patt YZ, *Medicine and Societal Issues at the Turn of the Millenium*, Chilean Society of Internal Medicine, Santiago, Chile, October 31, 2002.
71. Patt YZ, *Systemic Management of Metastatic Colorectal Cancer to the Liver*, First International Conference on Colon Cancer, Palm Beach, FL, November 1, 2002.
72. Patt YZ et al. Capecitabine (X) plus irinotecan (XELIRI) as first line treatment of metastatic colorectal cancer (MCRC) : Final safety findings from a phase II trial. Proceedings ASCO 2004 22: 270s, New Orleans, LA June5-8,2004
73. Patt YZ et al . Xeloda + irinotecan (XELIRI) as first line therapy for metastatic colo-rectal cancer (MCRC): Final response and survival analysis. Proceeding ESMO 2004, Vienna Austria October 31st-November 3rd 2004

Past Grant Support

| | |
|--|-------------|
| Principal Investigator In vitro immune restoration with thymic hormones #NCI POI Ca-05831 \$105,000 | 1979 - 1981 |
| Principal Investigator In vivo immune restoration with thymic hormones #NCI ROI CA-34674 \$135,000 | 1980 - 1983 |
| Principal Investigator American Contract Bridge League Charity Foundation Corporation \$25,000 | 1982 - 1987 |
| Principal Investigator Medtronic Inc. (DADS) Evaluation of Drug Administration Device \$125,000 | 1983 - 1987 |
| Principal Investigator Hybritech Phase I-II trial of ¹¹¹ In labeled MoAb anti-CEA in colorectal cancer \$105,000 | 1986 - 1990 |
| Marshall F. Hudson Fund for Research and Treatment of Liver Cancer 1990 \$25,000 | 1987 - |
| Principal Investigator Medtronic Inc. (DADS) Evaluation of Drug Administration Device \$45,000 | 1988 - 1990 |
| Principal Investigator Schering, Inc. Phase II trial of intravenous 5-FU and subcutaneous recombinant interferon-alpha for treatment for hepatocellular carcinoma \$14,000 | 1989 - 1991 |
| Principal Investigator ImmunoMedics, Inc. Tc99m labeled Fab' fragment of MoAb anti-CEA for imaging occult and known metastatic colorectal cancer \$60,000 | 1990 - 1991 |
| Stanley F. Peterson Memorial Fund for Research and Treatment of Liver Cancer \$5,000 | 1990 - 1992 |

| | |
|--|-----------|
| Principal Investigator ImmunoMedics, Inc. Tc99m labeled Fab' fragment MoAb anti-AFP for imaging hepatocellular Cancer - \$135,000 | 1991-1996 |
| Principal Investigator Schering Plough, Inc. Phase II trial of HAI of 5FU + rIFN α for metastatic colorectal cancer in the liver #ID93-024 \$65,000 | 1994-1996 |
| Principal Investigator Bristol-Myers, Oncology Division A phase II study of paclitaxel [NSC 125343] in patients with measurable biliary tree cancer, gall bladder cancer and cholangiocarcinoma \$10,000 | 1994-1996 |
| Principal Investigator Schering Plough, Inc. Phase II trial of HAI of platinol, rIFN α , adriamycin, and 5FU (PIAF) for hepatocellular cancer \$65,000 | 1994-1996 |
| Principal Investigator Schering Plough, Inc. Phase II trial of systemic PIAF (platinol, rIFN α 2b, adriamycin and 5-FU) in hepatocellular carcinoma #ID 95-126 \$120,000 | 1995-1998 |
| Phase II trial of systemic PIAF in biliary tree cancer #ID 95-132 \$37,000 | 1995-1997 |
| Phase II trial of HAI of 5FU and rIFN α 2b alternating with systemic CPT-11 #DM 97-272 \$39,000 | 1998-2000 |
| Principal Investigator Pharmacia Upjohn Phase II trial of HAI of 5FU and rIFN α 2b after mating with systemic CPT-11 #DM 97-272 \$127,000 | 1998-2000 |
| 2000 | 1998- |

| | |
|---|-------------|
| Principal Investigator Medtronic Evaluation of the ISO Med pump: a new implantable infusion device #ID98-300 \$60,000 | 1998-2000 |
| Principal Investigator Daiichi Pharmaceuticals Phase II trial of DX-8951F in biliary tree cancer #ID 99-379 - \$250,620 | August 1999 |
| Principal Investigator Daiichi Pharmaceuticals Phase II trial of DX-8951F in hepatocellular carcinoma #ID 98-145 \$250,620 | August 1999 |
| Principal Investigator McKinley Medical LLP Biology, prevention and treatment of hepatobiliary cancer. Unrestricted research gift \$276,000 | 1999-2002 |
| Principal Investigator Celgene Phase II trial of thalidomide, a putative neo-angiogenesis inhibitor in hepatocellular carcinoma #DM98-337 \$111,000 | 1999 - 2000 |
| Principal Investigator Schering Plough Fund for Research Support for an establishment of a cooperative HCC prevention trial in patients with HCV induced liver cirrhosis awaiting liver transplantation. \$48,500 | April 2000 |
| Principal Investigator Roche Laboratories A retrospective analysis of capecitabine in hepatobiliary malignancies \$36,000 | June 2000 |
| Principal Investigator Taiho Pharmaceutical Company, Inc. Phase I/II single-center, dose-escalating, pharmacokinetic, safety and efficacy study of oral TAC101 in patients with advanced hepatocellular carcinoma #ID01-007 \$359,385 | April 2001 |

October 2001

Hoffman-La Roche, Inc.

PI: (National) Y.Z.Patt

An open-label phase II study of continuous oral capecitabine in combination with intravenous irinotecan (Q3W) in patients with advanced and/or metastatic colorectal cancer

#ID01-314

\$67,888

Status: Study completed, presented at ASCO and ESMO 2004

Submitted for publication to JCO 2 weeks ago

Status : pending

Current Support at University of New Mexico

Industry

Colorectal Cancer:

Roche

Randomized Phase III trial of 1st line treatment of mCRC with either XELOX + Avastin Q 14 days

VS

XELOX + Avastin Q 21

days.

Status: To be activated at NMCCA and UNM

PI : Y.Z.Patt

Roche and Amgen

Investigator initiated Randomized trial of XELIRI + Panitumomab Q 14 days

Vs

XELIRI + Panitumomab Q 21 days

National PI : Y.Z.Patt

Support from both Roche and Amgen

Hepatocellular Carcinoma

Roche

Phase II trial of Xeloda + Avastin (bevacizumab) for the treatment of HCC in patients with platelet count > 40,000

PI: Yehuda Z. Patt

Status: Being negotiated with Genentech and Roche.

Award pending

Sanofi-Synthelabo

Phase II trial of Gemcitabine + Oxaliplatin for the treatment of HCC in Patients with >100,000 platelets
(Multi-Institutional)
PI: Yehuda Z. Patt
Award: approximately \$ 184,000.00 pending at \$ 6,000/patient.

Eximias
Phase III trial of Doxorubicin vs. Thymitaq in patients with HCC not previously exposed to anthracyclines
(Multi-Institutional)
National Oncology PI: Yehuda Z. Patt
Status: Accrual completed study closed.

Biliary tree Cancer

Planned:
Randomized Phase II trial of XELIRI with or with out panitumomab for the treatment of measurable biliary tree cancer.

PI: Y.Z.Patt
Status:
Negotiations with Roche, Pfizer and Amgen

Esophago-Gastric Carcinoma

Phase II trial of Docetaxel (Taxotere), XELODA and Oxalipaltin (DOXELOX)
For the treatment of measurable non-resectable Esophago-Gastric adenocarcinoma.

PI: Y.Z.Patt

Status: Indiscussion with Sanofi- Aventis awaiting approval.

Web Site

www.wentek.com/jean, *Multi-Disciplinary Approach to Hepatocellular Carcinoma*

Research activity:

Since I have arrived at the UNM CRTC I have devoted my energy to building a Clinical research program with therapeutic protocols that cover various clinical scenarios.

As seen in the attached list protocols have been designed to handle various stages of colorectal cancer, adenocarcinoma of the esophago-gastric region, biliary tree cancers and hepatocellular carcinoma.

Clinical Gastrointestinal cancer program;

Current status ; August 3, 2005

Efforts have focused on creating a menu of therapeutic options for patients with various GI malignancies covering as many of the clinical scenarios we are faced with, while managing GI malignancies.

Investigator Initiated trials have thus far been designed mostly in the form of Phase II, Phase I/II, or randomized Phase II trials. All of the latter trials have been generated at the CRTC of the University of New Mexico and are in the process of approval by the IRB and the NMCCA or are still in negotiations with industry. We participate in national/group phase III trials designed to answer questions we as a small institution can not answer by ourselves. (NSABP adjuvant colon cancer protocol, SWOG Pancreatic cancer protocol.) .

Listed below is a priority list that has been developed.
Please note that some of the protocols are still in negotiations for support and not yet completed or activated.
The status of each protocol is discussed.

Colorectal cancer:

Adjuvant treatment: NSABP C-08
A phase III trial comparing mFOLFOX-6 with or without Bevacizumab for the treatment of patients with resected Stage II and III Carcinoma of the Colon.

Rectal cancer : INST #3304-C
A phase II trial of XELOX + Celecoxib with concurrent radiation for patients with newly diagnosed resectable rectal cancer.

PI: Fa-Chyi Lee (IIT)

Comments: (1) Protocol is currently open
(2) This is a neo-adjuvant treatment trial
(3) Patients seem reluctant to join a celecoxib containing protocol.

Metastatic CRC 1st line Roche sponsored Phase III Randomized attempting to optimize the XELOX regimen administration by comparing

XELOX + Avastin Q 14 days
vs
XELOX + Avastin Q 21days.

Metastatic CRC Alliance # 0104C

For patients getting PI: Ian Rabinowitz.

XELOX as standard Rx The objective had been to determine Gene expression in tumors of patients being treated with Oxalipaltin containing regimens.

Comment: Only 2/26 patients. It has been difficult to convince patients to have fresh tissue biopsies. We need to explore the possibility of doing studies on existing tissues

Resectable mCRC: A randomized Phase II trial of Xeloda + Irinotecan (XELIRI) + Abgenix a humanized monoclonal antibody against EGFR for patients with respectable metastatic CRC.
The objective is to test 2 schedules of XELIRI Q 14 days and Q 21 days, with 2 different doses of Abgenix given Q 14 days or Q 21 days respectively.

The study requires tissue acquisition prior to any intervention and at the time of metastases resection for analysis by gene arrays to detect predictors of response to treatment and survival.

PI: Y.Z.Patt , this will be when approved a national IIT with UNM being the lead institution.

Status:

The concept has been approved by Roche for funding.

The study is awaiting approval by Amgen for both drug and support. .

Support for corollary studies may be requested from the PSRS if the study qualifies for support.

HCC Approximately 60% of all HCC patients are presenting with advanced liver cirrhosis which severely curtails therapeutic options. The thrust of the program is to provide treatment options to patients in various clinical scenarios.

Previously untreated patients:

Phase II trial of Patupilone a cell spindle inhibitor in patients with HCC; a Novartis sponsored trial

Previously untreated patients:

Phase II trial of capecitabine + bevacizumab in cirrhotic patients with HCC with patelet counts \geq 40,000/ μ L.

Status:

Protocol approved by Roche. Awaiting approval by Genentech. In case Genentech approves only drug and no support we will request support from the PSRS program.

Phase II trial of GEM-OX for HCC patients with $\geq 100,000$ platelets

Status: Study approved by Sanofi and by NMCCA, Awaiting HRRC approval.

Biliary Tree Cancer

Randomized Phase II trial of XELIRI (Xeloda + Irinotecan) with or without Panitumomab a human MoAb against EGFR for the treatment of measurable biliary tree cancers (gallbladder, intra- and extra-hepatic bile duct cancers)

Status:

Concept submitted to 2 different manufacturers of EGFR MoAbs namely Imclone/BMS for Cetuximab and Amgen for panitumomab.

Unfortunately, biliary tree cancers are not on the horizons of the companies in view of it's relative infrequency.

Plan: Try to get drug from Amgen and request support from PSRS provided a randomized phase II trial could be considered for such support. The innovative idea is to determine whether any reason to use EGFR blockade in the therapy or not.

Esophago-Gastric Carcinoma

Metastatic Esophago-Gastric carcinoma with measurable disease

Phase I/II trial of Docetaxel, Xeloda and Oxaliplatin (DOXELOX) for metastatic Esophago-Gastric Carcinoma

The objectives of the phase I part are to determine the MTD of docetaxel (Taxotere) when added to XELOX chemotherapy.

PI: Y.Z.Patt

Status: This is an IIT to be run in several institutions. LOI submitted to Sanofi-Aventis and we are awaiting a response.

Pancreatic Cancer

SWOG S0205: A phase III randomized open-label study comparing Gemcitabine plus Cetuximab (IMC-C225) vs Gemcitabine alone as 1st line therapy of patients with advanced pancreatic cancer.

Current enrollment; 9/15

These efforts will continue and clinical protocols that can not be adequately supported by industry will be submitted to the NCI for extra-mural funding in response to a recent RFP. The XELODA + Avastin protocol could be a candidate for seeking such support.

Epidemiology and prevention research in GI cancers:

The GI oncology Research focus group (GORFOG) has been created and is meeting regularly on alternating Wednesday in the PM to plan future GI research strategies.

Currently efforts are focused on creating a data bank that will complement our tissue bank as well as storage of serum and peripheral white blood cell samples of patients with colorectal cancer. The attempt is to capture patients from Bernalillo county to begin with in collaboration with NMCCA and the SEER cancer registry.

In response to a recent NIH RFP we plan to submit a study designed to **prevent** the progression from HCV induced liver cirrhosis to HCC. Details will be submitted following the completion of the grant submission.

Service:

Since gaining privileges at the UNMH on February 8th 2005, I have attended 7 weeks on the inpatient Hematology-Oncology service.

During those periods I have been supervising as well as teaching fellows and residents assigned to the Hematology – oncology service.

Out-patient:

I have had 2 clinic days per week during which I have been seeing new and follow-up patients, mostly those with GI malignancies.

I have implemented a multidisciplinary approach to the care of patients with GI malignancies. Patients that require the care of specialists for other disciplines such as surgical oncology, radiation oncology, interventional radiology, gastroenterology and hepatology are presented to the multi-disciplinary group during tumor board meetings. In most cases the consensus reached is implemented if acceptable to the patient.

Mentoring:

I have mentored mostly Dr. Fa-Chyi Lee, in terms of protocol design and preparation of data for publication. In fact Dr. Fa-Chyi Lee is the second author of a manuscript submitted recently to JCO regarding the treatment of mCRC with the XELIRI regimen.

I have worked with Dr. John Bibb, on his future research plans.

Grand Rounds and presentations in Albuquerque and elsewhere in NM

Daphne please list my presentations at Department of Medicine Grand Rounds Feb. 10th 2005
Department of Pathology Grand Rounds May 12th 2005
NMCCA need to ask Linda Green from NMCCA what date that was
NMCCA tumor board at ARMC July 21st 2005
Presentation at El Paso 8.5.05
Presentation at Almagordo 8.5.05

National and international meetings:

Presentation at The Budapest meeting

Presentation at the Barcelona International GI oncology meeting.

See whether you find any other presentations.

Please see what else needs to be done with that.